Henlez was founded by two former Novozymes employees Jeppe Christian Mouritsen and Rikke Nørregaard-Sarup. To realise their idea, they secured a mutually beneficial partnership and technology spin-out deal with Novozymes.
Henlez’s mission is not only to develop a new type of drug, but also on contributing to the public understanding of pathogenesis through collaborations. It is a key focus to Henlez to understand patient perspectives in detail, their problems, practical everyday and longterm challenges – in short working from the get go to map the detailed unmet need. The point is to develop a drug that is on one hand effective and safe, but on the other also affordable and user friendly.